Seeking Alpha

Bristol-Myers Squibb's (BMY) and AbbVie's (ABBV) Elotuzumab helped patients with...

Bristol-Myers Squibb's (BMY) and AbbVie's (ABBV) Elotuzumab helped patients with previously-treated multiple myeloma live for a median 33 months without the blood cancer getting worse in a Phase II trial. The drug was given with Celgene's (CELG) Revlimid and the steroid dexamethasone. Elotuzumab is also being tested in two Phase III trials for multiple myeloma. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)